ARBUTUS BIOPHARMA CORPORATION |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.325 USD | -2.49% |
|
+14.88% | +32.80% |
| May. 20 | Whitefort Capital Management Sends an Open Letter to Shareholders of Arbutus Biopharma | CI |
| May. 17 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
| Sales 2024 * | 9.04M 6.6M | Sales 2025 * | 8.08M 5.9M | Capitalization | 880M 642M |
|---|---|---|---|---|---|
| Net income 2024 * | -98M -71.54M | Net income 2025 * | -102M -74.46M | EV / Sales 2024 * | 97.4 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 109 x |
| P/E ratio 2024 * |
-8.73
x | P/E ratio 2025 * |
-8.68
x | Employees | 73 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.71% |
More Fundamentals
* Assessed data
More news
Latest transcript on Arbutus Biopharma Corporation
More recommendations
More press releases
| 1 day | -2.49% | ||
| 1 week | +14.88% | ||
| Current month | +21.61% | ||
| 1 month | +20.73% | ||
| 3 months | +13.70% | ||
| 6 months | +77.54% | ||
| Current year | +32.80% |
1 week
2.89
3.44
1 month
2.633.44
Current year
2.213.44
1 year
1.693.44
3 years
1.696.50
5 years
0.829.02
10 years
0.8229.93
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 14-06-30 | |
David Hastings
DFI | Director of Finance/CFO | 62 | 18-06-10 |
Karen Sims
CTO | Chief Tech/Sci/R&D Officer | 53 | 17-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 14-11-30 | |
James Meyers
BRD | Director/Board Member | 59 | 18-10-22 |
Daniel Burgess
BRD | Director/Board Member | 62 | 17-03-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 0 M€ | 0.00% | - | |
| 0.03% | 0 M€ | 0.00% | - | |
| 0.03% | 2 M€ | -.--% | ||
| 0.02% | 7 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 3.315 | -2.79% | 752 915 |
| 24-05-22 | 3.41 | +6.23% | 2,177,752 |
| 24-05-21 | 3.21 | +4.56% | 1,014,531 |
| 24-05-20 | 3.07 | +3.02% | 1,276,974 |
| 24-05-17 | 2.98 | +3.11% | 746,173 |
Delayed Quote Nasdaq, May 23, 2024 at 12:42 pm EDT
More quotes
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patientsâ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.
Sector
Pharmaceuticals
Calendar
2024-07-31
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.662
CAD
Average target price
6.029
CAD
Spread / Average Target
+29.32%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +32.80% | 644M | |
| -1.62% | 89.22B | |
| +1.32% | 40.49B | |
| -15.35% | 32.79B | |
| +64.13% | 26.23B | |
| -21.91% | 14.52B | |
| -7.61% | 13.09B | |
| -44.07% | 11.6B | |
| -13.06% | 11.5B | |
| +4.94% | 8.82B |
- Stock Market
- Equities
- ABUS Stock
